Leap Therapeutics Inc (LPTX) Stock Sees Value Buying After The News
Leap Therapeutics Inc (NASDAQ:LPTX) stock soared 21% on Monday. This rise comes after the company announced that it would present initial results from theDisTinGuish study. The study is a Phase IIa clinical trial for DKN-01, the company’s (DKK1) antibody used with tislelizumab and chemotherapy to treat patients with gastroesophageal junction or gastric cancer. The company has found that DKN-01, when combined with chemotherapy andtislelizumab as the first-line drug for gastroesophageal…








